Mathematical Models for Cancer Growth. Exponential Growth Model One model that has been used to describe tumor growth is the exponential growth model1.
Equation 1 The exponential does not describe the growth rate in vivo which slows are the tumor size increases. Gompertz Model Another model use to describe tumor dynamics is a Gompertz curve or Gompertz function. Equation 2 where N∞ is the plateau cell number which is reached at large values of r and the parameter b is related to the initial tumor growth rate. Even with Gompertzian growth, a single set of growth parameters is insufficient to model the clinical data. Model based on metabolic considerations To properly understand or derive a mathematical model for cancer growth, we must first understand the process of the ontogenetic development of an organism. Equation 3 where, B is the energy that an organism uses while at rest. We assume that variables Ec, Bc and mc all remain constant during an organism’s growth and is pertinent to a particular type of organism. Equation 4. Just 5% of terminally-ill cancer patients understand the depth of their situation.
Only a fraction of the cancer patients in the terminal stages of their illness fully understand their prognosis.
The findings suggest many patients are “kept in the dark”, even though they only have a couple months to live anymore. Credit: Pixabay The study was made by researchers at the Memorial Sloan Kettering Cancer Center, Cornell University and Weill Cornell Medicine. One of the authors, Holly Prigerson, the Director of the Center for Research on End of Life Care at Weill Cornell Medical Center, said the results were a “shock” and highlight a grave communication problem between doctors and patients. The doctors asked 178 cancer patients questions about their medical condition and future prognosis. Only five percent of the interviewed patients made statements that actually reflected the reality of their medical records before their illness was stage.
Radiology, News, Education, Service. Current breast MRI protocols are designed for diagnostic rather than screening purposes and are therefore time-consuming to acquire and read -- which contributes to the modality's relatively higher cost and limited availability, she noted in a presentation on 7 September at the American Society of Clinical Oncology (ASCO) 2013 Breast Cancer Symposium (BCS) in San Francisco.
A 56-year-old woman without a family history of breast cancer had a negative screening mammogram. MRI screening revealed a large, nonpalpable breast cancer in the immediate retro-areolar region of the left breast readily picked up by the maximum intensity projection (MIP) image (below). All images courtesy of Dr. Christiane Kuhl. Kuhl and colleagues investigated whether a streamlined protocol, consisting only of the first postcontrast subtracted images and their maximum intensity projection (MIP) reconstructions, would be suitable for screening purposes. Dr. Related Reading Copyright © 2013 AuntMinnieEurope.com. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. Importance Glioblastoma is the most devastating primary malignancy of the central nervous system in adults.
Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. Objective To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. Design, Setting, and Participants After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea.
Adding Electric-field Therapy Slows Brain Tumors - American Council on Science and Health. A surprising finding in a new JAMA study: adding alternating electrical-field application to standard chemotherapy (temozolomide) leads to a small, but significant, benefit in terms of progression-free and overall survival.
The study was a team effort, involving no less than 30 researcher-co-authors from 25 medical centers worldwide. The lead author is Roger Stupp MD of the Universities of Zurich and Lausanne, Switzerland. Meet In Italy for Life Sciences 2015. Tumori: scoperta la strada per soffocarli. Medscape Log In. A phase-I study of poliovirus-mediated remission of lethal brain cancer shows striking results - American Council on Science and Health (ACSH) As highlighted on the CBS News show, “60 Minutes,” a several-year early-stage trial of poliovirus as an immunological stimulant to attack and kill brain cancer cells is yielding astounding results, in a small group of patients with previously-intractable glioblastoma multiforme.
Using standard biotech methods, (very similar to those used in GM technology), the virus was modified so that it was missing certain components of the natural virus, and therefore, cannot cause polio. The study is taking place at Duke University in North Carolina. Led by Drs. Darell Bigner and Henry Friedman, the 22 patients overall received varying doses of the polio viral infusion, in an effort to stem the advance of one of the worst, most aggressive and treatment-refractory tumors known to man: grade-4 astrocytoma, brain cancer with wildly aberrant cells that normally kill within a few weeks, or months at the most.
Imaging in Glioblastoma Multiforme. T1-weighted axial gadolinium-enhanced magnetic resonance image demonstrates an enhancing tumor of the right frontal lobe.
Image courtesy of George Jallo, MD. T2-weighted image demonstrates the same lesion as in the previous image, with notable edema and midline shift. Un video spiega come mandare il cancro in cortocircuito. Medscape Log In. Silicon Byosistems, la start up acquistata da Menarini. Per Silicon Byosistems il 2013 è stato un anno straordinario, cominciato con il premio Leonardo Start up assegnato in febbraio dalla presidenza della Repubblica.
E concluso con l’ingresso nella galassia Menarini, primo gruppo farmaceutico italiano. Tutto comincia con la tesi di laurea in ingegneria elettronica di uno studente pugliese fuori sede a Bologna, Gianni Medoro, su una nuova tecnologia in grado di isolare in modo automatico le cellule tumorali presenti nel sangue sfruttando i principi della dielettroforesi. Presa la laurea, Medoro, oggi Chief Scientific Officer, continua a lavorare con il collega Nicolò Manaresi, oggi Chief Technology Officer, sulla sua idea che nel 2005 diventa diventa un progetto di impresa che, grazie anche all’ingresso nel team di una figura senior come Giuseppe Giorgini (il CEO, con una importante esperienza in una società californiana di biotecnologie) attira in breve capitali importanti.
Breast Cancer Imaging: MRI’s Role in Current Practice. Un bersaglio comune per combattere cancro e diabete. Le apnee notturne aumentano il rischio di tumore. Sign In. A Cheap, Accurate Cancer Sensor, Created By A 15-Year-Old. Every year, the Intel International Science and Engineering Fair wows us with the ingenuity of high school students.
This year’s first place winner is particularly impressive. Jack Andraka, a 15-year-old student from Maryland, came up with a paper sensor that detects pancreatic cancer 168 times faster than current tests. It’s also 90% accurate, 400 times more sensitive, and 26,000 times less expensive than today’s methods. In short: It’s a lot better. Andraka was inspired to focus on pancreatic cancer because a friend’s brother was killed by the disease. Andraka’s dip-stick sensor can test urine or blood for a certain protein (mesothelin) that indicates the existence of the specific cancer. This isn’t Andraka’s first science fair. Naevi in silico, controlla i tuoi nei con lo smartphone. Tumori, 1 su 6 è causato da infezioni. Le cellule staminali che alimentano i tumori.